Emergent BioSolutions signs $87 mln deal to make AstraZeneca's COVID-19 vaccine in U.S.
June 11, 2020 at 09:03 AM EDT
Emergent BioSolutions Inc said on Thursday it signed a $87 million deal to make AstraZeneca Plc's experimental COVID-19 vaccine in the United States, as the British drugmaker looks to ramp up its efforts to bring a vaccine to the market.
